MediWound Ltd. (NASDAQ:MDWD) has been given an average rating of “Buy” by the six research firms that are presently covering the firm. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $13.25.
Several research analysts have recently weighed in on MDWD shares. Wells Fargo & Co. started coverage on MediWound in a research note on Wednesday, August 17th. They set an “outperform” rating and a $14.00 target price for the company. Jefferies Group reduced their target price on MediWound from $15.00 to $13.00 and set a “buy” rating for the company in a research note on Friday, July 29th. Finally, Zacks Investment Research downgraded MediWound from a “hold” rating to a “sell” rating in a research note on Wednesday, October 5th.
Shares of MediWound (NASDAQ:MDWD) opened at 5.25 on Monday. The stock’s 50 day moving average is $6.15 and its 200-day moving average is $7.31. MediWound has a 52 week low of $5.00 and a 52 week high of $10.47. The stock’s market capitalization is $114.82 million.
MediWound (NASDAQ:MDWD) last announced its earnings results on Monday, November 14th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.26). The business earned $0.52 million during the quarter, compared to the consensus estimate of $0.61 million. MediWound had a negative return on equity of 148.23% and a negative net margin of 1,776.06%. The business’s quarterly revenue was up 420.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.17) EPS. On average, analysts anticipate that MediWound will post ($0.99) earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Migdal Insurance & Financial Holdings Ltd. purchased a new position in MediWound during the second quarter valued at approximately $13,302,000. Wellington Management Group LLP increased its position in MediWound by 10.7% in the first quarter. Wellington Management Group LLP now owns 1,044,703 shares of the biopharmaceutical company’s stock valued at $8,431,000 after buying an additional 100,723 shares in the last quarter. Baker BROS. Advisors LP purchased a new position in MediWound during the third quarter valued at approximately $1,740,000. Morgan Stanley increased its position in MediWound by 91,055.5% in the third quarter. Morgan Stanley now owns 182,311 shares of the biopharmaceutical company’s stock valued at $1,404,000 after buying an additional 182,111 shares in the last quarter. Finally, United Services Automobile Association increased its position in MediWound by 1.3% in the third quarter. United Services Automobile Association now owns 125,080 shares of the biopharmaceutical company’s stock valued at $963,000 after buying an additional 1,640 shares in the last quarter. 27.49% of the stock is owned by hedge funds and other institutional investors.